Related Experiment Video

Updated: Jul 5, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Association between plasma pregnancy-associated plasma protein a and restenosis after percutaneous coronary

Xu-Ping Li1, Sheng Hua Zhou, Jian Jun Tang

  • 1Department of Cardiology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.

Circulation Journal : Official Journal of the Japanese Circulation Society
|April 29, 2008
PubMed

Insights

Elevated pregnancy-associated plasma protein A (PAPP-A) levels predict restenosis after coronary angioplasty. Lower PAPP-A levels are associated with reduced restenosis and major adverse cardiac events, highlighting PAPP-A as a key predictor.

Area of Science:

  • Cardiovascular Medicine
  • Biomarker Discovery
  • Interventional Cardiology

Background:

  • Restenosis following percutaneous coronary angioplasty (PCI) is a significant clinical challenge.
  • Identifying reliable predictors of restenosis is crucial for improving patient outcomes.
  • This study investigates plasma pregnancy-associated plasma protein A (PAPP-A) as a potential biomarker for restenosis.

Purpose of the Study:

  • To evaluate the association between baseline plasma PAPP-A levels and the incidence of restenosis after coronary angioplasty.
  • To determine if PAPP-A can independently predict restenosis and major adverse cardiac events.
  • To explore the correlation of PAPP-A with other inflammatory markers and platelet activation markers.

Main Methods:

  • Baseline blood samples were collected from 184 patients undergoing PCI.
  • Plasma levels of PAPP-A, high-sensitivity C-reactive protein (hsCRP), and soluble CD40 ligand (sCD40L) were measured.
  • Quantitative coronary angiography was performed at a median of 6.4 months to assess restenosis (>=50% diameter stenosis).

Main Results:

  • Patients with restenosis exhibited significantly higher baseline PAPP-A levels compared to those without (19.24 vs 11.95 mIU/L; p<0.001).
  • PAPP-A levels strongly correlated with follow-up diameter stenosis (r=0.54, p=0.01) and late lumen loss.
  • Lower PAPP-A levels (<12.51 mIU/L) were associated with significantly lower rates of restenosis (28.4% vs 50.6%; p<0.001) and major adverse cardiac events (15.6% vs 51.1%; p<0.001).

Conclusions:

  • Plasma PAPP-A is a strong independent predictor of restenosis after coronary angioplasty.
  • PAPP-A levels can stratify patients at risk for restenosis and adverse cardiac events.
  • These findings suggest PAPP-A could be a valuable biomarker in managing patients post-PCI.
Abstract

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...